Phan Trieu Phu

Phu Phan Trieu

Research Coordinator

Oxford University Clinical Research Unit

Tel: (+84) 92 400 8121








Research Keywords: 

Targeted next-generation sequencing, multidrug-resistant tuberculosis, TB vaccine



I started working for tuberculosis research in 2017, focusing on latent tuberculosis prevention programmes. I joined Oxford University Clinical Research Unit in 2018 to begin working on a project to identify risk factors for poor treatment outcomes of multidrug-resistant tuberculosis patients. I moved to the UK in 2020 to start my master’s degree in public health under the Chevening Scholarship funded by FCDO. In 2022, I started working on an epidemiologic study to assess the interferon gamma release assay (IGRA) positivity, and to build capacity to conduct a tuberculosis vaccine efficacy study, funded by The Bill & Melinda Gates Medical Research Institute. With the supervision of Professor Tim Walker, I have been contracted by WHO to conduct a systematic review of diagnostic accuracy of targeted next-generation sequencing technologies for detection of drug resistance among people diagnosed with TB.


Key Publications:

Van, L. H., Phu, P. T., Vinh, D. N., Son, V. T., Hanh, N. T., Nhat, L. T. H., Lan, N. H., Vinh, T. van, Trang, N. T. M., Ha, D. T. M., Thwaites, G. E., & Thuong, N. T. T. (2020). Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: A retrospective study. BMC Infectious Diseases, 20(1)


Web Links of Interest